BioCentury | Jan 31, 2020
Distillery Therapeutics

CLEC14A-positive stem cell transplants for muscle regeneration

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Transplantation with muscle-derived CLEC14A-positive stem cells could regenerate muscle following injury, despite lacking expression of known myogenic regulator PAX7. The myogenic cells were isolated from muscle fiber fragments that underwent...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Jul 25, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Zebrafish expressing human PAX3 and FOXO1 could be used to screen therapies for rhabdomyosarcoma. Zebrafish harboring M214K-mutant p53, engineered to express human PAX3 and FOXO1 and injected with a ubiquitous promoter...
BioCentury | Jul 10, 2018
Distillery Therapeutics


INDICATION: Sarcoma Cell culture and mouse studies suggest combining Mekinist trametinib with IGF1R inhibitors could help treat PAX3-PAX7 fusion-negative rhabdomyosarcoma. Screening of a panel of 1,912 approved or tool compound small molecule inhibitors in a...
BioCentury | Apr 10, 2018
Preclinical News

Researchers identify coding, non-coding driver mutations in MM

Scientists from the Institute of Cancer Research (London, U.K.) identified coding and non-coding driver mutations involved in newly diagnosed multiple myeloma, suggesting the genes could be targeted to treat the disease. The research was published...
BioCentury | Dec 22, 2016
Translation in Brief

Pin the tail

Stanford University researchers have provided preclinical proof of concept that adding polyadenine (polyA) tails to atypical sites on mRNAs could treat disease. Although the team applied the strategy to the transcript of the fibrosis target,...
BioCentury | Dec 6, 2016
Distillery Therapeutics


INDICATION: Sarcoma Cell culture studies suggest inhibiting CHD4 could help treat PAX-FOX1 fusion gene -positive rhabdomyosarcomas. In two human rhabdomyosarcoma cell lines positive for the PAX-FOX1 fusion oncogene, shRNA targeting CHD4 decreased cell numbers and...
BioCentury | Jun 16, 2016
Emerging Company Profile

No cells left behind a cocktail of growth factors and transcription factors that include PDX1 , MAFA and PAX4...
...Glucagon MAFA ( RIPE3b1 ) - v-maf musculoaponeurotic fibrosarcoma oncogene homolog A PAX4 - Paired box 4...
BioCentury | Apr 14, 2016
Product R&D

AACR by the numbers

See Figure: Top indications See Table: Novel cancer targets at AACR 2016 See Figure: Top institutions and companies See Figure: Top targets Tables Novel cancer targets at AACR 2016 Breast cancer amplified sequence 1 (BCAS1)...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
Items per page:
1 - 10 of 29